Transgene Company Top Insiders

TRGNF Stock  USD 1.59  0.00  0.00%   
Transgene employs about 143 people. The company is managed by 10 executives with a total tenure of roughly 22 years, averaging almost 2.0 years of service per executive, having 14.3 employees per reported executive. Examination of Transgene's management performance can provide insight into the company performance.
Eric Quemeneur  President
Executive Vice President Vice President - Research & Development, Member of the Management Committee
JeanPhilippe Del  President
Vice President - Finance, Member of the Management Committee
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Transgene SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Transgene Management Team Effectiveness

The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.

Transgene Workforce Comparison

Transgene SA is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 64,484. Transgene adds roughly 143 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (1.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.39.

Transgene SA Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Transgene SA Price Series Summation is a cross summation of Transgene price series and its benchmark/peer.

Transgene Notable Stakeholders

A Transgene stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Transgene often face trade-offs trying to please all of them. Transgene's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Transgene's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Eric QuemeneurExecutive Vice President Vice President - Research & Development, Member of the Management CommitteeProfile
JeanPhilippe DelVice President - Finance, Member of the Management CommitteeProfile
Elisabetta CastelliDirector of Investor RelationsProfile
Maud MDVP OfficerProfile
Gaelle StadtlerVP HRProfile
Hedi BrahimCEO DirectorProfile
Lucie LarguierDirector IRProfile
Steven RPhVP OfficerProfile
LLM JDGen VPProfile
Philippe SlosHead LaboratoryProfile

About Transgene Management Performance

The success or failure of an entity such as Transgene SA often depends on how effective the management is. Transgene management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Transgene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Transgene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.

Transgene Workforce Analysis

Traditionally, organizations such as Transgene use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Transgene within its industry.

Transgene Manpower Efficiency

Return on Transgene Manpower

Revenue Per Employee69.9K
Revenue Per Executive999.3K
Net Loss Per Employee136.6K
Net Loss Per Executive2M
Working Capital Per Employee188.8K
Working Capital Per Executive2.7M

Complementary Tools for Transgene Pink Sheet analysis

When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios